CA3137400A1 - Therapeutic drug for dyskinesia - Google Patents

Therapeutic drug for dyskinesia Download PDF

Info

Publication number
CA3137400A1
CA3137400A1 CA3137400A CA3137400A CA3137400A1 CA 3137400 A1 CA3137400 A1 CA 3137400A1 CA 3137400 A CA3137400 A CA 3137400A CA 3137400 A CA3137400 A CA 3137400A CA 3137400 A1 CA3137400 A1 CA 3137400A1
Authority
CA
Canada
Prior art keywords
tandospirone
levodopa
prodrug
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3137400A
Other languages
English (en)
French (fr)
Inventor
Mitsumasa Kurita
Yuki Ikeda
Mitsuhiro Nakato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of CA3137400A1 publication Critical patent/CA3137400A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3137400A 2019-04-26 2020-04-24 Therapeutic drug for dyskinesia Pending CA3137400A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/395,531 2019-04-26
US16/395,531 US10758535B1 (en) 2019-04-26 2019-04-26 Therapeutic drug for dyskinesia
PCT/JP2020/017652 WO2020218487A1 (en) 2019-04-26 2020-04-24 Therapeutic drug for dyskinesia

Publications (1)

Publication Number Publication Date
CA3137400A1 true CA3137400A1 (en) 2020-10-29

Family

ID=72241591

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3137400A Pending CA3137400A1 (en) 2019-04-26 2020-04-24 Therapeutic drug for dyskinesia

Country Status (13)

Country Link
US (3) US10758535B1 (enExample)
EP (1) EP3958972A4 (enExample)
JP (2) JP7695891B2 (enExample)
KR (1) KR20220004640A (enExample)
CN (1) CN113646045A (enExample)
AU (1) AU2020260895A1 (enExample)
BR (1) BR112021021184A8 (enExample)
CA (1) CA3137400A1 (enExample)
EA (1) EA202192928A1 (enExample)
MX (1) MX2021013070A (enExample)
PH (1) PH12021552681A1 (enExample)
SG (1) SG11202111852TA (enExample)
WO (1) WO2020218487A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11559525B2 (en) * 2019-04-26 2023-01-24 Sumitomo Pharma Co., Ltd. Therapeutic drug for dyskinesia
CA3168199A1 (en) 2020-02-19 2021-08-26 Eri ICHIBAYASHI Transdermal absorption preparation
JPWO2022045336A1 (enExample) * 2020-08-31 2022-03-03
CA3221728A1 (en) * 2021-06-30 2023-01-05 Grace S. LIANG Valbenazine for use in the treatment of dyskinesia due to cerebral palsy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507303A (en) 1981-12-22 1985-03-26 Sumitomo Chemical Company, Limited Succinimide derivatives, compositions and method of use
JPH11228414A (ja) 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
WO2005117886A1 (ja) 2004-06-01 2005-12-15 Hisamitsu Pharmaceutical Co., Inc. 貼付剤
ATE413166T1 (de) 2004-11-22 2008-11-15 Hisamitsu Pharmaceutical Co Transdermales pflaster enthaltend einen schmelzpunktsenkenden hilfsstoff
JP4873871B2 (ja) 2005-02-28 2012-02-08 久光製薬株式会社 粘着剤及び貼付剤
WO2008044336A1 (en) 2006-10-11 2008-04-17 Hisamitsu Pharmaceutical Co., Inc. Crystal-containing adhesive preparation
EP2729176A1 (en) 2011-07-05 2014-05-14 Contera Pharma APS The use of serotonin receptor agonists for treatment of movement disorders
MY169068A (en) 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP3897641B1 (en) * 2018-12-20 2023-11-15 Contera Pharma A/S Treatment of movement disorders

Also Published As

Publication number Publication date
WO2020218487A1 (en) 2020-10-29
EP3958972A1 (en) 2022-03-02
KR20220004640A (ko) 2022-01-11
MX2021013070A (es) 2021-11-17
EP3958972A4 (en) 2023-01-04
AU2020260895A1 (en) 2021-12-23
JP2022529661A (ja) 2022-06-23
EA202192928A1 (ru) 2022-02-07
JP7695891B2 (ja) 2025-06-19
SG11202111852TA (en) 2021-11-29
BR112021021184A2 (enExample) 2021-12-14
US20220193075A1 (en) 2022-06-23
US20210060015A1 (en) 2021-03-04
US10758535B1 (en) 2020-09-01
JP2025072496A (ja) 2025-05-09
BR112021021184A8 (pt) 2023-02-28
CN113646045A (zh) 2021-11-12
PH12021552681A1 (en) 2022-09-19

Similar Documents

Publication Publication Date Title
WO2020218487A1 (en) Therapeutic drug for dyskinesia
US10004744B2 (en) Therapeutic approaches for treating Parkinson's disease
KR20150002642A (ko) 근위축성 측삭 경화증 치료용 신규 조성물
TW201707704A (zh) 激酶調節及其適應症
JP2010526820A (ja) 気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
JP6634445B2 (ja) ブスピロン代謝産物の使用
CN107405347A (zh) 用于治疗处理或美容处理过量体脂肪的nk‑3受体拮抗剂
US20230241062A1 (en) Therapeutic drug for motor complications in parkinson's disease
US20230201199A1 (en) Therapeutic drug for dyskinesia
AU2007259256A1 (en) Combination preparations comprising bifeprunox and L-DOPA
KR20070029740A (ko) 통증 치료를 위한 레복세틴의 용도
CN112423749A (zh) 用于外部使用的医学制剂
JP2015529196A (ja) ラサギリンの非経口製剤
CN110402142A (zh) 含局麻药的酸性乳液组合物
EA046505B1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
JPH09500375A (ja) パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用
RU2173150C1 (ru) Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
JP2023082771A (ja) パーキンソン病治療薬
JP2020033322A (ja) パーキンソン病の治療のための医薬組成物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251009

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229